Brought to you by 
Lonza Biologics evaluates Chromos Molecular Systems' ACE
26 Jul 2002
Executive Summary
Chromos Molecular Systems (artificial chromosome expression) and Swiss company Lonza Biologics (therapeutic antibodies) have entered into an agreement to evaluate Chromos's ACE (Artificial Chromosome Expression) gene delivery and expression technology.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Lonza Biologics evaluates Chromos Molecular Systems' ACE
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice